Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) Accumulated Expenses: 2011-2019

Historic Accumulated Expenses for EyePoint Pharmaceuticals (EYPT) over the last 8 years, with Mar 2019 value amounting to $2.9 million.

  • EyePoint Pharmaceuticals' Accumulated Expenses fell 9.05% to $2.9 million in Q1 2019 from the same period last year, while for Mar 2019 it was $2.9 million, marking a year-over-year decrease of 9.05%. This contributed to the annual value of $3.7 million for FY2018, which is 11.86% down from last year.
  • As of Q1 2019, EyePoint Pharmaceuticals' Accumulated Expenses stood at $2.9 million, which was down 22.83% from $3.8 million recorded in Q4 2018.
  • EyePoint Pharmaceuticals' Accumulated Expenses' 5-year high stood at $4.2 million during Q2 2017, with a 5-year trough of $1.4 million in Q1 2015.
  • For the 3-year period, EyePoint Pharmaceuticals' Accumulated Expenses averaged around $3.3 million, with its median value being $3.3 million (2018).
  • As far as peak fluctuations go, EyePoint Pharmaceuticals' Accumulated Expenses soared by 146.39% in 2016, and later plummeted by 38.55% in 2017.
  • EyePoint Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $3.6 million in 2015, then increased by 3.63% to $3.7 million in 2016, then slumped by 38.55% to $2.3 million in 2017, then skyrocketed by 67.51% to $3.8 million in 2018, then declined by 9.05% to $2.9 million in 2019.
  • Its Accumulated Expenses stands at $2.9 million for Q1 2019, versus $3.8 million for Q4 2018 and $3.3 million for Q3 2018.